ATOSSA THERAPEUTICS, INC. (ATOS) Form 10-K Annual Reports
ATOSSA THERAPEUTICS, INC. (ATOS) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: ATOS
CIK: 1488039
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Ernst & Young LLP
Auditor SinceSince 12/31/2023 12:00:00 AM
Lead Engagement PartnerMatthew Stover
Audit LocationSeattle, Washington, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 8-K | 2026-10-09 | 2026-10-08 | 8-K | 0001193125-26-418560 | View SEC Doc Filr Page |
| 8-K | 2026-09-29 | 2026-09-29 | 8-K | 0001193125-26-406036 | View SEC Doc Filr Page |
| 8-K | 2026-09-18 | 2026-09-18 | 8-K | 0001193125-26-395694 | View SEC Doc Filr Page |
| 8-K | 2026-08-07 | 2026-08-07 | 8-K | 0001193125-26-339292 | View SEC Doc Filr Page |
| 10-Q | 2026-08-07 | 2026-06-30 | 10-Q | 0001193125-26-339257 | View SEC Doc Filr Page |
| 424B5 | 2026-06-12 | — | 424B5 | 0001193125-26-268597 | View SEC Doc Filr Page |
| 8-K | 2026-06-11 | 2026-06-10 | 8-K | 0001193125-26-266717 | View SEC Doc Filr Page |
| 4 | 2026-05-14 | 2026-05-12 | 4 | 0001193125-26-224521 | View SEC Doc Filr Page |
| 4 | 2026-05-14 | 2026-05-12 | 4 | 0001193125-26-224148 | View SEC Doc Filr Page |
| 4 | 2026-05-14 | 2026-05-12 | 4 | 0001193125-26-224140 | View SEC Doc Filr Page |
| 4 | 2026-05-14 | 2026-05-12 | 4 | 0001193125-26-224135 | View SEC Doc Filr Page |
| 4 | 2026-05-14 | 2026-05-12 | 4 | 0001193125-26-224133 | View SEC Doc Filr Page |
| 4 | 2026-05-14 | 2026-05-12 | 4 | 0001193125-26-224125 | View SEC Doc Filr Page |
| 8-K | 2026-05-08 | 2026-05-08 | 8-K | 0001193125-26-213439 | View SEC Doc Filr Page |
| 10-Q | 2026-05-08 | 2026-03-31 | 10-Q | 0001193125-26-213423 | View SEC Doc Filr Page |
| 8-K | 2026-05-08 | 2026-05-07 | 8-K | 0001193125-26-213373 | View SEC Doc Filr Page |
| 8-K | 2026-04-16 | 2026-04-13 | 8-K | 0001193125-26-158030 | View SEC Doc Filr Page |
| 4 | 2026-03-31 | 2026-03-27 | 4 | 0001193125-26-134861 | View SEC Doc Filr Page |
| 4 | 2026-03-30 | 2026-03-26 | 4 | 0001193125-26-132644 | View SEC Doc Filr Page |
| ARS | 2026-03-30 | 2025-12-31 | ARS | 0001193125-26-131954 | View SEC Doc Filr Page |
| DEF 14A | 2026-03-30 | 2026-03-30 | DEF 14A | 0001193125-26-131807 | View SEC Doc Filr Page |
| 10-K | 2026-03-25 | 2025-12-31 | 10-K | 0001193125-26-124396 | View SEC Doc Filr Page |
| 8-K | 2026-03-25 | 2026-03-25 | 8-K | 0001193125-26-124393 | View SEC Doc Filr Page |
| PRE 14A | 2026-03-20 | 2026-03-20 | PRE 14A | 0001193125-26-117826 | View SEC Doc Filr Page |
| 8-K | 2026-02-20 | 2026-02-19 | 8-K | 0001193125-26-061412 | View SEC Doc Filr Page |